Compare Amphastar Pharmaceuticals Inc (AMPH) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.3 (market cap $826.08M), while Las Vegas Sands Corp. trades at $46.67 (market cap $30.94B). The key difference: Las Vegas Sands Corp. is far larger — about 37.5× Amphastar Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 2.36% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LVS | |
|---|---|---|
Market Cap | $826.08M | $30.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $69.49 |
52-Week Low | $16.87 | $46.06 |
Enterprise Value | $1.22B | $43.33B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
LVS trades at $46.69, up 0.52% with a bearish technical signal despite strong fundamentals. The company demonstrates robust revenue growth, reaching $13.02B in 2025 with consistent earnings beats and a 13.41% net margin. Analyst consensus remains strongly bullish with a $66.89 price target, though technical indicators show selling pressure with support at $46.
LVS presents a compelling investment case with strong operational performance and analyst support, though technical weakness and high debt levels pose risks. The stock offers significant upside potential from current levels if fundamental strength continues, but investors should monitor debt management and Macau market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
